Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML
ClinicalTrials.gov study NCT02182596. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
ClinicalTrials.gov study NCT06470841. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndr
ClinicalTrials.gov study NCT00038805. IPD Sharing: Not stated. Countries: 1. Publications: 0.
MIF Involvement in AML
ClinicalTrials.gov study NCT03918655. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
ClinicalTrials.gov study NCT00069992. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
ClinicalTrials.gov study NCT06247787. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Avapritinib in CBF-AML With KIT Mutations
ClinicalTrials.gov study NCT05821738. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
ClinicalTrials.gov study NCT06263387. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
ClinicalTrials.gov study NCT05199051. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
ClinicalTrials.gov study NCT00373373. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
ClinicalTrials.gov study NCT06449482. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
ClinicalTrials.gov study NCT03459859. IPD Sharing: NO. Countries: 1. Publications: 0.
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
ClinicalTrials.gov study NCT03135054. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
ClinicalTrials.gov study NCT06370000. IPD Sharing: NO. Countries: 1. Publications: 0.
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
ClinicalTrials.gov study NCT06892223. IPD Sharing: NO. Countries: 1. Publications: 0.
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
ClinicalTrials.gov study NCT04986657. IPD Sharing: YES. Countries: 1. Publications: 0.
Venetoclax-Decitabine in Untreated Elderly/Unfit AML
ClinicalTrials.gov study NCT07117422. IPD Sharing: NO. Countries: 1. Publications: 0.
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
ClinicalTrials.gov study NCT02870777. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Ce
ClinicalTrials.gov study NCT02957032. IPD Sharing: Not stated. Countries: 1. Publications: 0.
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT00136448. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.